Drug
GSK 1004723 clinical trials
- studies test it
- 3
- open now
- 0
- in phase 3
- 0
- first study started
- 2007
How studies write it
Studies that test it under each name
Development codes
- GSK1004723
- 1
Studies by the year they started
3 studies that test it; most in 2007 (1)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2008 | 1 |
| 2009 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 3 · Other 0
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses GSK 1004723 is read from its arms, and is right about nine times in ten.
Testing it · 3
- Single and Repeat Dose First Time in Human Study for an Intranasal H1/H3 Dual Antagonist in Healthy Male SubjectsCompletedPhase 1GlaxoSmithKlineNCT00694993Written as GSK1004723
- 723/726 Proof of Concept Study in Allergen Challenge Chamber in HannoverCompletedPhase 2GlaxoSmithKlineNCT00972504Written as GSK1004723 1000mcg
- Allergen Challenge Chamber Study With Single Dose Intranasal GSK1004723 Compared With PlaceboCompletedPhase 2GlaxoSmithKlineNCT00824356Written as GSK1004723 (200mg)
Codes
What other systems call GSK 1004723 · ClinicalTrials.gg INT005846
- Wikidata Q27288388gsk-1004723One source Wikidata
| System | Code | Name there | Checked by |
|---|---|---|---|
| Wikidata | Q27288388 | gsk-1004723 | One source Wikidata |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.